Enovis Q1 net sales $406M (+9% organic), adj EPS $0.44; raises FY2023 outlook

Enovis CORP

2023-Q1 EPS reported -$0.43 revenue$406,151,000

Recon segment organic growth 19% (P&R +4%); total organic sales +9%.
Adjusted EBITDA $56M (13.9% of sales, +120 bps YoY); net loss from cont ops $0.42/sh.
FY 2023 outlook raised: organic rev growth 6-7% (prev 5-6%), adj EBITDA $259-267M, adj EPS $2.18-2.32.
Agreement to acquire Novastep (bunion segment) expected to close Q2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Enovis CORP reported first quarter ended March 31, 2023 results: revenue $406 million, net income net loss from continuing operations of $23 million, EPS adjusted earnings per share of $0.44. Guidance raised.

Period: first quarter ended March 31, 2023
Revenue: $406 million
Net income: net loss from continuing operations of $23 million
EPS: adjusted earnings per share of $0.44
Guidance: raised
Result: reported results

Exact text from the filing

will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. First Quarter 2023 Financial Results Enovis’ first quarter net sales of $406 million grew 8% from the prior year quarter, including 9% organic growth and a 1.5% currency headwind. Sales in the Reconstructive segment grew 19%, both as reported and organically, and

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Enovis CORP filing history →

Source: SEC EDGAR

accession 0001420800-23-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.